ICAM1 and atherosclerosis: Paricalcitol treatment for 12 weeks to CKD patients in stage 3–4 induces a decline relative to placebo in concentrations of ICAM-1 positive MPs, where soluble ICAM-1 is a marker known to be implicated in atherosclerosis and to correlate with risk of future cardiovascular events [53].